Leicester among world first in novel cancer prevention trialNovember 04, 2002University of Leicester team pioneers tests of new drug with ‘red wine compound’ Leicester has been selected as one of the first centres in the world to trial a revolutionary new cancer prevention drug, based on a natural compound found in red wine. This will form a major part of the cancer prevention research at the University of Leicester. Cancer researchers from the University’s Department of Oncology, based at the Leicester Royal Infirmary, have been awarded just over £1 million sterling ($1.7 million) along with the University of Michigan. The award, from the US National Cancer Institute (NCI), the major US government body which funds and co-ordinates cancer research, is the first time that a group outside America has been funded by the NCI for the early clinical development of a drug that may prevent cancer. The money will be used by the Cancer Biomarker and Prevention Group of the University of Leicester, in conjunction with the Comprehensive Cancer Centre at the University of Michigan, to conduct preclinical and clinical evaluation of resveratrol, a natural compound found in red wine. Professor Will Steward, of the University of Leicester, said: “Resveratrol is a natural agent found in grapes, peanuts and several berries. It is present in fruit juice from these berries and in wine. Consumption of resveratrol has been proposed as one possible explanation for the low incidence of cardiovascular disease in Southern European countries with high red wine consumption, and resveratrol has been shown to possess anti-inflammatory and anti-cancer activity in experimental models.” “Since resveratrol may be of value in preventing cancer, the NCI are funding early clinical studies of pure resveratrol capsules in healthy volunteers and patients with early cancer. These studies will be conducted in Leicester and at the University of Michigan.” The principal investigators, in the UK are Professors William Steward, Andreas Gescher and Peter Farmer and Drs David Boocock, David Hemingway and Ricky Sharma. Professor Steward added: “Over the past four years, the University of Leicester has built up the largest integrated cancer prevention group in Europe. Laboratory-based scientists and clinicians work closely together to develop novel drugs which have promise for reducing the risk of developing cancer. This award is a major advance and we hope it will enable us to take resveratrol forward to become a valuable agent to reduce the number of people who develop cancer in the future.” The research group attracted international publicity a few years ago when they investigated the cancer-fighting properties of curcumin, an ingredient in curries. Professor Steward said: “The Leicester team has been involved with the early clinical development of the potential cancer preventive agent curcumin, derived from the dietary spice turmeric. Encouraging results are being obtained from this. The Cancer Biomarker and Prevention Group are also planning early clinical development of other dietary constituents that may help in the fight against cancer.” The principal investigator in the USA, Professor Dean Brenner, said: “The award of this competitive grant by the US NCI is a major achievement. In the USA, such awards are given only to teams who are able to successfully integrate their laboratory research scientists with clinical investigators, and awards made to teams outside the US are rare.” “Foreign awards are given only to groups who are able to provide expertise not available in the USA. The successful completion of this contract signifies that the University of Leicester group is considered a world class translational research group and I am thrilled to be able to work closely with such an outstanding group.” FACTFILE Can patients with cancer take part? - No, the initial trial has to be with healthy volunteers When will the trials begin? - The trials will begin in Spring 2003 Where will they take place? - University of Leicester and Leicester Royal Infirmary How will people know when the trial is about to start? - Flyers will be distributed in the University of Leicester and Leicester Royal Infirmary How will people be selected for the trials? - Selection made from completed information on flyers of healthy, mainly young volunteers, a 50/50 split males and females. Leicester, University of |
|||||||||||||||||||||
| Related Cancer Current Events and Cancer News Articles Laser therapy can aggravate skin cancer High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Reflux esophagitis due to immune reaction, not acute acid burn, UT Southwestern researchers report Contrary to current thinking, a condition called gastroesophageal reflux disease (GERD) might not develop as a direct result of acidic digestive juices burning the esophagus, UT Southwestern Medical Center researchers have found in an animal study. Engineer designs micro-endoscope to seek out early signs of cancer Traditional endoscopes provide a peek inside patients' bodies. Now, a University of Florida engineering researcher is designing ones capable of a full inspection. UAB Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Cancers' Sweet Tooth May Be Weakness The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. New on-off 'switch' triggers and reverses paralysis in animals with a beam of light In an advance with overtones of Star Trek phasers and other sci-fi ray guns, scientists in Canada are reporting development of an internal on-off "switch" that paralyzes animals when exposed to a beam of ultraviolet light. Toward explaining why hepatitis B hits men harder than women Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Scientists find molecular trigger that helps prevent aging and disease Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease? UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. More Cancer Current Events and Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||